FDA Approved: BRILINTA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for BRILINTA (ticagrelor) submitted by AstraZeneca Pharmaceuticals LP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome
• Myocardial Infarction
• Stroke
• Unstable Angina

Drugs mentioned

• BRILINTA (ticagrelor)

Snippet

SUPPL AP for BRILINTA (TICAGRELOR)